A former 24-week-old premature infant was treated with intravitreal ranibizumab (Lucentis; Genentech, South San Francisco, CA) in one eye and conventional laser in the other eye for aggressive posterior retinopathy of prematurity in both eyes. Fluorescein angiography performed at 149 weeks of age showed persistent avascularity of the temporal peripheral retina in the ranibizumabtreated eye. This case report confirms the need for long-term follow-up of patients treated with ranibizumab monotherapy.
|Original language||English (US)|
|Number of pages||4|
|Journal||Ophthalmic Surgery Lasers and Imaging Retina|
|State||Published - Jan 2017|
ASJC Scopus subject areas